Universe Pharmaceuticals Inc is a company focused on the development, manufacturing, and distribution of high-quality pharmaceutical products, particularly in the realm of traditional Chinese medicine
The company aims to leverage advanced technologies and sustainable practices to create innovative therapeutics that address various health conditions. With a commitment to research and development, Universe Pharmaceuticals also emphasizes the importance of quality control and regulatory compliance in its operations, ensuring that its products meet rigorous industry standards. Through these efforts, the firm seeks to enhance healthcare outcomes and provide accessible solutions for patients globally.
Stay updated with the latest market activity on Friday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Ji’an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company’s listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Rule. However, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split on November 18, 2024, or within the prior one-year period.
